All Stories

  1. The Cost of Good Intentions: How EU rules shape German competitiveness

    Article • Research in Economics, September 2026, Elsevier

    Dr Jörg Mahlich

  2. Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review

    Article • Journal of Comparative Effectiveness Research, July 2026, Becaris Publishing Limited

    Dr Jörg Mahlich

  3. Willingness to Pay for Treatment Attributes in Diffuse Large B-Cell Lymphoma: A Discrete Choice Experiment in Japan

    Article • Clinical Drug Investigation, April 2026, Springer Science + Business Media

    Dr Jörg Mahlich

  4. Risk attitudes and value of hope: survey results from Japanese hematologists and oncologists treating patients with diffuse large B-cell lymphoma

    Article • Scientific Reports, March 2026, Springer Science + Business Media

    Dr Jörg Mahlich

  5. Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma

    Article • Journal of Cancer Research and Clinical Oncology, July 2025, Springer Science + Business Media

    Dr Jörg Mahlich

  6. Identification of Adjustment Variables in Indirect Comparisons: A Rapid Review of CAR-T Therapies for Diffuse Large B-Cell Lymphoma

    Article • Cancers, April 2025, MDPI AG

    Dr Jörg Mahlich

  7. Survival outcomes of patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation in Germany: real-world evidence from an administrative database between 2010 and 2019

    Article • Frontiers in Oncology, October 2024, Frontiers

    Dr Jörg Mahlich

  8. Switching from Cigarettes to Heated Tobacco Products in Japan—Potential Impact on Health Outcomes and Associated Health Care Costs

    Article • Healthcare, September 2024, MDPI AG

    Dr Jörg Mahlich

  9. Systematic Literature Review to Identify Influencing Factors of Efficacy and Safety Outcomes of Chimeric Antigen Receptor T-Cell Therapies in Large B-Cell Lymphoma

    Article • Blood, November 2023, American Society of Hematology

    Dr Jörg Mahlich

  10. Survival Outcomes of Patients with Diffuse Large B-Cell Lymphoma Who Received Autologous Stem Cell Transplantation in Germany - Real World Evidence from an Administrative Database

    Article • Blood, November 2023, American Society of Hematology

    Dr Jörg Mahlich

  11. The philosophy of pharmaceutical regulation—Paternalism or freedom of choice?

    Article • Frontiers in Medicine, October 2023, Frontiers

    Dr Jörg Mahlich

  12. Unlocking the value of innovative medicines: Insights from the advanced therapy medicinal products (ATMP) innovation systems in Germany and Sweden

    Article • Health Policy and Technology, June 2023, Elsevier

    Dr Jörg Mahlich

  13. Zahlungsbereitschaft für Insektizid-imprägnierte Moskitonetze zur Malariaprophylaxe in Subsahara-Afrika – eine systematische Literaturrecherche

    Article • Gesundheitsökonomie & Qualitätsmanagement, May 2023, Thieme Publishing Group

    Dr Jörg Mahlich

  14. Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database

    Article • Journal of Cancer Research and Clinical Oncology, March 2023, Springer Science + Business Media

    Dr Jörg Mahlich

  15. Medication Adherence of People Living with HIV in Japan—A Cross-Sectional Study

    Article • Healthcare, February 2023, MDPI AG

    Dr Jörg Mahlich

  16. Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data Analysis

    Article • Oncology and Therapy, November 2022, Springer Science + Business Media

    Dr Jörg Mahlich

  17. Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany

    Article • Blood, November 2022, American Society of Hematology

    Dr Jörg Mahlich

  18. Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL) - a Retrospective Health Claims Data Analysis

    Article • Blood, November 2022, American Society of Hematology

    Dr Jörg Mahlich

  19. Culture and COVID-19-related mortality: a cross-sectional study of 50 countries

    Article • Journal of Public Health Policy, August 2022, Springer Science + Business Media

    Dr Jörg Mahlich

  20. Incidence of graft-versus-host-disease in Germany: evidence from health care claims data

    Article • Journal of Public Health, August 2022, Springer Science + Business Media

    Dr Jörg Mahlich

  21. Treatment Pathways and Health Outcomes of German Patients with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Health Claims Data Analysis

    Article • Drugs - Real World Outcomes, July 2022, Springer Science + Business Media

    Dr Jörg Mahlich

  22. Health Resource Utilization and Associated Health Care Costs of Biologic Disease‐Modifying Antirheumatic Drugs in German Patients With Psoriatic Arthritis

    Article • Arthritis Care & Research, June 2022, Wiley

    Dr Jörg Mahlich

  23. Incidence of graft-versus-host-disease in Germany – evidence from health care claims data

    Article • April 2022, Springer Science + Business Media

    Dr Jörg Mahlich

  24. Telemedicine in Japan: Challenges and Opportunities

    Article • January 2022, Springer Science + Business Media

    Dr Jörg Mahlich

  25. Culture And COVID-19 Related Mortality- A Cross Sectional Study of 53 Countries

    Article • November 2021, Springer Science + Business Media

    Dr Jörg Mahlich

  26. Hospitalisierungen und Behandlungskosten von Schizophreniepatienten nach Umstellung auf Depot-Antipsychotika

    Article • Gesundheitsökonomie & Qualitätsmanagement, August 2021, Thieme Publishing Group

    Dr Jörg Mahlich

  27. Estimation of Health-State Utility Values and Factors Driving Health-Related Quality of Life in People Living with HIV and AIDS and Receiving cART in Germany: Baseline Analysis of a Cohort Study

    Article • Applied Research in Quality of Life, March 2021, Springer Science + Business Media

    Dr Jörg Mahlich

  28. Persistence With Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis

    Article • Crohn’s & Colitis 360, February 2021, Oxford University Press (OUP)

    Dr Jörg Mahlich

  29. Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study

    Article • Rheumatology and Therapy, February 2021, Springer Science + Business Media

    Dr Jörg Mahlich

  30. Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis

    Article • Health Economics Review, January 2021, Springer Science + Business Media

    Dr Jörg Mahlich

  31. Bright line or lottery? On significance and value in medical decision making

    Article • Journal of Market Access & Health Policy, January 2021, MDPI AG

    Dr Jörg Mahlich

  32. Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics

    Article • Clinical Drug Investigation, December 2020, Springer Science + Business Media

    Dr Jörg Mahlich

  33. Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany

    Article • Journal of Dermatological Treatment, July 2020, Taylor & Francis

    Dr Jörg Mahlich

  34. Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study

    Article • PLOS One, May 2020, PLOS

    Dr Jörg Mahlich

  35. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study

    Article • Journal of Medical Economics, March 2020, Taylor & Francis

    Dr Jörg Mahlich

  36. Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study

    Article • Clinical Drug Investigation, March 2020, Springer Science + Business Media

    Dr Jörg Mahlich

  37. Die Bedeutung von Big Data für klinische Entwicklungen und den Marktzugang

    Article • January 2020, Springer Science + Business Media

    Dr Jörg Mahlich

  38. Understanding the global measurement of willingness to pay in health

    Article • Journal of Market Access & Health Policy, January 2020, MDPI AG

    Dr Jörg Mahlich

  39. R&D Management in the Japanese Pharmaceutical Industry

    Article • January 2020, World Scientific Pub Co Pte Lt

    Dr Jörg Mahlich

  40. Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital

    Article • Neurology and Therapy, August 2019, Springer Science + Business Media

    Dr Jörg Mahlich

  41. Drug Survival of Biological Therapies for Psoriasis Treatment in Germany and Associated Costs: A Retrospective Claims Database Analysis

    Article • Advances in Therapy, May 2019, Springer Science + Business Media

    Dr Jörg Mahlich

  42. Shared Decision-Making and Patient Satisfaction in Japanese Rheumatoid Arthritis Patients: A New “Preference Fit” Framework for Treatment Assessment

    Article • Rheumatology and Therapy, May 2019, Springer Science + Business Media

    Dr Jörg Mahlich

  43. Co-insurance and health care utilization in Japanese patients with rheumatoid arthritis: a discontinuity regression approach

    Article • International Journal for Equity in Health, January 2019, Springer Science + Business Media

    Dr Jörg Mahlich

  44. Shared Decision-Making in Patients With Prostate Cancer in Japan: Patient Preferences Versus Physician Perceptions

    Article • Journal of Global Oncology, December 2018, American Society of Clinical Oncology (ASCO)

    Dr Jörg Mahlich

  45. Biologic treatment of Japanese patients with inflammatory bowel disease

    Article • BMC Gastroenterology, November 2018, Springer Science + Business Media

    Dr Jörg Mahlich

  46. Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan

    Article • PharmacoEconomics - Open, October 2018, Springer Science + Business Media

    Dr Jörg Mahlich

  47. Returns on different types of investment in the global pharmaceutical industry

    Article • Managerial and Decision Economics, October 2018, Wiley

    Dr Jörg Mahlich

  48. Cross-national drug price comparisons with economic weights in external reference pricing in Germany

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, October 2018, Taylor & Francis

    Dr Jörg Mahlich

  49. Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs

    Article • Drugs - Real World Outcomes, August 2018, Springer Science + Business Media

    Dr Jörg Mahlich

  50. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database

    Article • BMC Dermatology, July 2018, Springer Science + Business Media

    Dr Jörg Mahlich

  51. Hospitalization costs and length of stay of Japanese children with respiratory syncytial virus

    Article • Medicine, July 2018, Wolters Kluwer Health

    Dr Hiroshi Kubo, Dr Jörg Mahlich

  52. Cultural beliefs, utility values, and health technology assessment

    Article • Cost Effectiveness and Resource Allocation, June 2018, Springer Science + Business Media

    Dr Jörg Mahlich

  53. Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan

    Article • American Journal of Men s Health, May 2018, SAGE Publications

    Dr Jörg Mahlich

  54. Burden of illness of chemotherapy in castration-resistant prostate cancer patients in Japan: a retrospective database analysis

    Article • Current Medical Research and Opinion, May 2018, Taylor & Francis

    Dr Jörg Mahlich

  55. Productivity loss of caregivers of schizophrenia patients: a cross-sectional survey in Japan

    Article • Journal of Mental Health, April 2018, Taylor & Francis

    Dr Jörg Mahlich

  56. Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data

    Article • PLOS One, April 2018, PLOS

    Dr Jörg Mahlich

  57. Cost of Depression in Japanese Patients with Rheumatoid Arthritis: Evidence from Administrative Data

    Article • Rheumatology and Therapy, February 2018, Springer Science + Business Media

    Dr Jörg Mahlich

  58. Hematologists’ Preferences for First-line Therapy Characteristics for Multiple Myeloma in Japan: Attribute Rating and Discrete Choice Experiment

    Article • Clinical Therapeutics, February 2018, Elsevier

    Dr Jörg Mahlich

  59. Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study

    Article • Drugs - Real World Outcomes, November 2017, Springer Science + Business Media

    Dr Jörg Mahlich

  60. The underrated prevalence of depression in Japanese patients with rheumatoid arthritis - evidence from a Nationwide survey in Japan

    Article • BMC Rheumatology, November 2017, Springer Science + Business Media

    Dr Jörg Mahlich

  61. Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, November 2017, Taylor & Francis

    Dr Jörg Mahlich

  62. Impact of patient characteristics and treatment procedures on hospitalization cost and length of stay in Japanese patients with influenza: A structural equation modelling approach

    Article • Influenza and Other Respiratory Viruses, October 2017, Wiley

    Dr Jörg Mahlich, Dr Hiroshi Kubo

  63. Productivity loss of Japanese patients with rheumatoid arthritis – A cross-sectional survey

    Article • Modern Rheumatology, August 2017, Oxford University Press (OUP)

    Dr Jörg Mahlich

  64. The relationship between socio-demographic factors, health status, treatment type, and employment outcome in patients with inflammatory bowel disease in Japan

    Article • BMC Public Health, July 2017, Springer Science + Business Media

    Dr Jörg Mahlich

  65. FRI0177 The underrated prevalence of depression in patients with rheumatoid arthritis

    Article • June 2017, BMJ

    Dr Jörg Mahlich

  66. Productivity and deadweight losses due to relapses of schizophrenia in Japan

    Article • May 2017, Dove Medical Press

    Dr Jörg Mahlich

  67. Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib

    Article • PharmacoEconomics - Open, April 2017, Springer Science + Business Media

    Dr Jörg Mahlich

  68. Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis

    Article • Clinical Drug Investigation, March 2017, Springer Science + Business Media

    Dr Jörg Mahlich

  69. A NEW HEALTH TECHNOLOGY ASSESSMENT SYSTEM FOR JAPAN? SIMULATING THE POTENTIAL IMPACT ON THE PRICE OF SIMEPREVIR

    Article • International Journal of Technology Assessment in Health Care, January 2017, Cambridge University Press

    Dr Jörg Mahlich

  70. Shared Decision Making and Treatment Satisfaction in Japanese Patients with Inflammatory Bowel Disease

    Article • Digestive Diseases, January 2017, Karger Publishers

    Dr Jörg Mahlich

  71. The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany

    Article • Journal of Pharmaceutical Policy and Practice, December 2016, Taylor & Francis

    Dr Jörg Mahlich

  72. Preferences Regarding Shared Decision-Making in Japanese Inflammatory Bowel Disease Patients

    Article • Advances in Therapy, November 2016, Springer Science + Business Media

    Dr Jörg Mahlich

  73. Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents

    Article • Current Medical Research and Opinion, October 2016, Taylor & Francis

    Dr Jörg Mahlich

  74. Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan

    Article • Patient Preference and Adherence, August 2016, Dove Medical Press

    Dr Jörg Mahlich

  75. Analysis of contemporary HIV/AIDS health care costs in Germany

    Article • Medicine, June 2016, Wolters Kluwer Health

    Dr Jörg Mahlich

  76. Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison

    Article • BMC Infectious Diseases, December 2015, Springer Science + Business Media

    Dr Jörg Mahlich

  77. Unemployment, health, and education of HIV-infected males in Germany

    Article • International Journal of Public Health, October 2015, Springer Science + Business Media

    Dr Jörg Mahlich

  78. Determinants of physician's office visits and potential effects of co‐payments: evidence from Austria

    Article • The International Journal of Health Planning and Management, September 2015, Wiley

    Dr Jörg Mahlich

  79. Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach

    Article • BMC Infectious Diseases, July 2015, Springer Science + Business Media

    Dr Jörg Mahlich

  80. Treatment strategies for treatment naïve HIV patients in Germany: evidence from claims data

    Article • SpringerPlus, July 2015, Springer Science + Business Media

    Dr Jörg Mahlich

  81. Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan

    Article • ClinicoEconomics and Outcomes Research, May 2015, Dove Medical Press

    Dr Jörg Mahlich

  82. Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data

    Article • April 2015, Taylor & Francis

    Dr Jörg Mahlich

  83. A potential gender bias in assessing quality of life – a standard gamble experiment among university students

    Article • ClinicoEconomics and Outcomes Research, April 2015, Taylor & Francis

    Dr Jörg Mahlich

  84. Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan

    Article • Journal of Medical Economics, March 2015, Informa Healthcare

    Dr Jörg Mahlich

  85. Häufigkeiten antiretroviraler Therapie in Sekundärdaten von gesetzlichen Krankenkassen in Deutschland

    Article • Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen, January 2015, Elsevier

    Dr Jörg Mahlich

  86. Fehlkodierungen von HIV/AIDS-Diagnosen und deren Bedeutung für den morbiditätsorientierten Risikostrukturausgleich

    Article • Gesundheitsökonomie & Qualitätsmanagement, December 2014, Thieme Publishing Group

    Dr Jörg Mahlich

  87. A Potential Gender Bias in the Quality of Life - an Exploratory Standard Gamble Experiment Among Economics Students

    Article • Value in Health, November 2014, Elsevier

    Dr Jörg Mahlich

  88. R&D Investments, Intangible Capital and Profitability in the Pharmaceutical Industry

    Article • Value in Health, November 2014, Elsevier

    Dr Jörg Mahlich

  89. What Drives Unemployment of HIV-Infected Patients in Germany?

    Article • Value in Health, November 2014, Elsevier

    Dr Jörg Mahlich

  90. Pharmaceutical regulation in Europe and its impact on corporate R&D

    Article • Health Economics Review, October 2014, Springer Science + Business Media

    Dr Jörg Mahlich

  91. Krankheitskosten von HIV-Patienten unter antiretroviraler Therapie in Deutschland – Ergebnisse einer 48-Wochen-Interimsanalyse im Rahmen der prospektiven multizentrischen Kohortenstudie „CORSAR“

    Article • Das Gesundheitswesen, September 2014, Thieme Publishing Group

    Dr Jörg Mahlich

  92. Evaluating the concordance of physician judgments and patient preferences on AIDS/HIV therapy - a Discrete Choice Experiment

    Article • Health Economics Review, December 2013, Springer Science + Business Media

    Dr Jörg Mahlich

  93. Budget Impact of Paliperidone Palmitate in Austria

    Article • Value in Health, November 2013, Elsevier

    Dr Jörg Mahlich

  94. Pharmaceutical Regulation in Europe and Its Impact on Corporate R&D

    Article • Value in Health, November 2013, Elsevier

    Dr Jörg Mahlich

  95. Cost-Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany

    Article • Value in Health, November 2013, Elsevier

    Dr Jörg Mahlich

  96. Erratum to: Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany

    Article • Applied Health Economics and Health Policy, September 2013, Springer Science + Business Media

    Dr Jörg Mahlich

  97. Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany

    Article • Applied Health Economics and Health Policy, August 2013, Springer Science + Business Media

    Dr Jörg Mahlich

  98. Medikamentenadhärenz in der Asthmatherapie - eine strukturierte Übersicht

    Article • Pneumologie, June 2013, Thieme Publishing Group

    Dr Jörg Mahlich

  99. Patient preferences for HIV/AIDS therapy - a discrete choice experiment

    Article • Health Economics Review, May 2013, Springer Science + Business Media

    Dr Jörg Mahlich

  100. Budget Impact Analyse von Paliperidon Palmitat im österreichischen Versorgungskontext

    Article • PharmacoEconomics German Research Articles, April 2013, Springer Science + Business Media

    Dr Jörg Mahlich

  101. PIH40 What Do Health Economists Expect from Their Employer- Results from an On-Line Survey in Germany

    Article • Value in Health, November 2012, Elsevier

    Dr Jörg Mahlich

  102. PMH18 Treatment Patterns and Costs in Patients With Schizophrenia in Germany

    Article • Value in Health, November 2012, Elsevier

    Dr Jörg Mahlich

  103. PIN33 Corsar-Study (Cost and Resource Utilisation Study in Antiretroviral Treated Patients)

    Article • Value in Health, November 2012, Elsevier

    Dr Jörg Mahlich

  104. Berufliche Erwartungen und Erfahrungen von angehenden und berufstätigen Gesundheitsökonomen - Ergebnisse einer online Umfrage

    Article • Gesundheitsökonomie & Qualitätsmanagement, October 2012, Thieme Publishing Group

    Dr Jörg Mahlich

  105. HIV/AIDS-Diagnosen und Verordnung von antiretroviraler Therapie in Deutschland – Häufigkeiten, Kosten und deren Bedeutung für die Kalkulation des morbiditätsorientierten Risikostrukturausgleichs

    Article • DMW - Deutsche Medizinische Wochenschrift, September 2012, Thieme Publishing Group

    Dr Jörg Mahlich

  106. Economic burden of osteoporotic fractures in Austria

    Article • Health Economics Review, June 2012, Springer Science + Business Media

    Dr Jörg Mahlich

  107. Direkte und indirekte Kosten von osteoporotisch bedingten Frakturen in Österreich

    Article • Das Gesundheitswesen, March 2012, Thieme Publishing Group

    Dr Jörg Mahlich

  108. Korean Science and Technology in an International Perspective

    Article • January 2012, Springer Science + Business Media

    Dr Jörg Mahlich

  109. PHP138 Intangible Capital and Return on Assets in the Pharmaceutical Industry

    Article • Value in Health, November 2011, Elsevier

    Dr Jörg Mahlich

  110. Institutionelle Determinanten von F&E-Investitionen

    Article • Journal of Business Economics, August 2011, Springer Science + Business Media

    Dr Jörg Mahlich

  111. Introduction: The Challenge of Innovation and Technology for Korea as a Newly Advanced Economy Revisited

    Article • July 2011, Springer Science + Business Media

    Dr Jörg Mahlich

  112. R&D MANAGEMENT OF JAPANESE PHARMACEUTICAL FIRMS

    Article • International Journal of Innovation and Technology Management, June 2011, World Scientific Pub Co Pte Lt

    Dr Jörg Mahlich

  113. Intangibles Kapital und Rentabilität in der Pharmaindustrie

    Article • Die Unternehmung, January 2011, Nomos Verlag

    Dr Jörg Mahlich

  114. Wettbewerb zwischen Generika und Originalherstellern in Österreich am Beispiel der ACE-Hemmer

    Article • Das Gesundheitswesen, December 2010, Thieme Publishing Group

    Dr Jörg Mahlich

  115. PMS23 BURDEN OF ILLNESS OF OSTEOPOROSIS IN AUSTRIA

    Article • Value in Health, November 2010, Elsevier

    Dr Jörg Mahlich

  116. Patents and performance in the Japanese pharmaceutical industry: An institution-based view

    Article • Asia Pacific Journal of Management, January 2009, Springer Science + Business Media

    Dr Jörg Mahlich

  117. The Japanese Pharmaceutical Industry in Transition: Has Higher Research Orientation Resulted in Higher Market Value?

    Article • Asian Business & Management, February 2007, Springer Science + Business Media

    Dr Jörg Mahlich

  118. Innovation and Technology in Korea

    Article • January 2007, Springer Science + Business Media

    Dr Jörg Mahlich

  119. The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan

    Article • Review of Industrial Organization, March 2006, Springer Science + Business Media

    Dr Jörg Mahlich

  120. Anmerkungen zur Profitabilität der Pharmaindustrie

    Article • WiSt - Wirtschaftswissenschaftliches Studium, January 2006, Verlag Franz Vahlen GmbH

    Dr Jörg Mahlich

  121. Wirtschaftspolitik für wissensintensive Branchen am Beispiel der Pharmaindustrie

    Article • Zeitschrift für Wirtschaftspolitik, December 2005, De Gruyter

    Dr Jörg Mahlich

  122. Die japanische Pharmaindustrie

    Article • Springer Science + Business Media

    Dr Jörg Mahlich

  123. Introduction: Korea as a Newly Advanced Economy and the Role of Technology and Innovation

    Article • Springer Science + Business Media

    Dr Jörg Mahlich

  124. The Technological Competencies of Korea’s Firms: A Patent Analysis

    Article • Springer Science + Business Media

    Dr Jörg Mahlich